ri-1

RI-1 (RAD51 inhibitor 1) is a RAD51 inhibitor (IC50: 5-30 μM).

1,2,3-Tri-10(Z)-undecenoyl glycerol is a triglyceride composed of 10-undecenoic acid esterified at the sn-1, sn-2, and sn-3 positions.

DDRI-18 is a novel small molecule inhibitor that regulates the DNA damage response with sensitizing and anticancer activities, inhibits non-homologous end-joining (NHEJ) DNA repair and enhances the cytotoxicity of anticancer DNA damage compounds.

TRi-1 is irreversible inhibitor of cytosolic thioredoxin reductase 1 (TXNRD1), with an IC50 of 12 nM. TRi-1 has little mitochondrial toxicity for anticancer therapy

ARI-1 is a receptor tyrosine kinase-like orphan receptor 1 (ROR1) inhibitor that binds to ROR1's extracellular Frizzled domain, effectively inhibiting aberrant ROR1 expression linked to non-small cell lung cancer (NSCLC) and EGFR-TKI-induced drug resistance. It modulates PI3K/AKT/mTOR signaling pathways in a ROR1-dependent manner and demonstrates potent inhibition of NSCLC cell proliferation and migration, exhibiting antitumor activity in vivo [1].

1,2,3-Tri-13(E)-docosenoyl glycerol, a triacylglycerol featuring 13(E)-docosenoic acid at the \(sn-1\), \(sn-2\), and \(sn-3\) positions, transiently elevates heart triglyceride levels in weanling rats when administered as 15% of a calcium-deficient diet, with levels returning to baseline after 28 days.

1,2,3-Tri-11(Z)-eicosenoyl glycerol, a triacylglycerol with 11(Z)-eicosenoic acid at the sn-1,sn-2, and sn-3 positions, serves as an internal standard for quantifying triacylglycerols in seed and olive oils.

Tri-11(E)-eicosenoin is a lipid utilized in the formulation of lipid nanoparticles (LNP) for drug delivery applications.

Tri-11(Z),14(Z),17(Z)-eicosatrienoin is a lipid utilized in formulating lipid nanoparticles (LNPs) for drug delivery purposes.

Tri-11(Z)-octadecenoin is a lipid used in the formulation of lipid nanoparticles (LNP) for drug delivery applications.

Tri-10(Z)-nonadecenoin is a lipid utilized in the preparation of lipid nanoparticles (LNP) for drug delivery applications.

Tri-11(Z),14(Z)-eicosadienoin is a lipid utilized in the formulation of lipid nanoparticles (LNP) for drug delivery.

Tri-10(Z)-pentadecenoin (1,2,3-Tri-10(Z)-pentadecenoyl glycerol) is a triglyceride in which the sn-1, sn-2, and sn-3 positions are all esterified with 10(Z)-pentadecenoic acid.

AHR Inhibitor I-103 is an aryl hydrocarbon receptor (AHR) inhibitor with anticancer activity used in the study of breast cancer and acute myeloid leukemia.

(Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a potent and selective antagonist of cannabinoid receptor type 1 (CB1R) and inducible nitric oxide synthase (iNOS), with a binding affinity (Ki) of 5.7 nM for CB1R. It holds promise as an investigative tool in liver fibrosis research due to these characteristics.

Zevaquenabant ((S)-MRI-1867), a dual cannabinoid CB1 receptor and inducible NOS (iNOS) antagonist, is orally bioavailable and peripherally restricted. It effectively mitigates obesity-induced chronic kidney disease (CKD).

IST-622 is a unique topoisomerase inhibitor, showing significant growth-inhibitory effects against large-cell lung cancer (Lu-116) and gastric adenocarcinoma (St-4).

Kri 1314 is a cyclohexyl-norstatine-containing dipeptide renin inhibitor which has potential for the treatment of hypertension.

Monlunabant is a selective CB1 antagonist that blocks CB1 receptor signaling to reduce appetite and fat accumulation, making it suitable for research on obesity and metabolic syndrome. Monlunabant binds to hCB1 and hCB2 with Ki values of 0.3 nM and 613 nM, respectively.

F-CRI1, a potent STING agonist with a dissociation constant (K d) of 40.62 nM, is an 18F-labeled radioactive probe employed for visualizing STING in the tumor microenvironment [1].

(R)-Monlunabant ((R)-MRI-1891) is a CB1 receptor antagonist used in obesity and metabolic disease research [1].

Prosupride (GRI 1665) is a neuroleptic agent that selectively blocks dopaminergic receptors.

(R)-Zevaquenabant ((R)-MRI-1867) is the enantiomer of Zevaquenabant. Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual antagonist of the cannabinoid CB1 receptor and inducible nitric oxide synthase (iNOS). It is beneficial in improving chronic kidney disease (CKD) caused by obesity.

RI(dl)-2 TFA is a potent and selective inhibitor of RAD51-mediated D-loop formation, with an IC50 of 11.1 μM, and inhibits homologous recombination (HR) activity in human cells with an IC50 of 3.0 μM [1].